Many parallels exist between hashish and psychedelics. Amongst them are the varied therapeutic results for which each lessons of medicine at the moment are being investigated, from preventing ache and irritation to aiding remedy of some psychiatric problems. Additionally on the listing: Alzheimer’s Illness, the most typical neurodegenerative illness with as many as 6.2 million People dwelling with the situation. (The subsequent most prevalent is Parkinson’s Illness at 1.2 million.)
On the psychedelic entrance, a overview article printed final 12 months within the journal Frontiers in Synaptic Neuroscience1 makes a robust case for LSD and psilocybin as potential therapies for this progressively disabling situation. A examine now underway at Johns Hopkins College’s Middle for Psychedelic and Consciousness Analysis and one other printed in 20192 by psychedelic medication firm Eleusis sign severe curiosity in Alzheimer’s among the many area’s heavy hitters.
And on the planet of hashish science, the plant has been studied as a possible remedy for Alzheimer’s Illness since at the least the flip of the century. Right now curiosity within the topic is increased than ever. The scientific writer Frontiers lately issued a name for papers on “focusing on the endocannabinoidome in neurodegenerative problems,” recognizing the topic as a “scorching analysis space.” (The time period “endocannabinoidome” refers back to the expanded endocannabinoid system, together with extra mediators, enzymes, and molecular targets.)
In September 2021 alone, three papers appeared within the scientific literature summarizing a lot of what’s identified about Alzheimer’s Illness and the endocannabinoid system.
CBD for Alzheimer’s Illness
An article printed within the journal Mind Sciences3 evaluations how the endocannabinoid system (ECS) could also be concerned within the growth of Alzheimer’s Illness – and the way cannabidiol (CBD) and different cannabinoids could also be used to assist deal with it. The dialogue will get fairly technical, however listed here are the authors’ highlights of what the science from the final couple many years suggests:
- Postmortem evaluation has revealed adjustments to a number of parts of the ECS within the brains of Alzheimer’s sufferers. Expression of CB1 cannabinoid receptors is decreased, whereas expression of CB2 receptors is markedly elevated within the frontal or parahippocampal cortex, “in all probability in a time-dependent method.”
- Elevated expression of CB2 receptors is pronounced in and round amyloid plaques (aggregates of abnormally configured proteins which can be thought of a trademark of Alzheimer’s Illness and cognitive decline), indicating a correlation between the ECS and plaque deposition.
- Expression of the enzymes FAAH [fatty acid amide hydrolase] and MAGL [monoacylglycerol lipase] – which metabolize the endocannabinoids anandamide and 2-Arachidonoylglycerol (2-AG) , respectively – will increase within the brains of Alzheimer’s sufferers. So too does expression of a 3rd key enzyme, DAGL [diacylglycerol lipase], which synthesizes 2-AG.
- Given the modulatory results of cannabinoids on the ECS, cannabinoids could also be good candidates for treating Alzheimer’s Illness. Medical trials have already reported that cannabinoids could be helpful for decreasing some signs in sufferers with Alzheimer’s or dementia.
Whereas each THC and CBD provide promise on this respect and are identified to be neuroprotective, “the concomitant psychotropic results of THC pose an issue,” the authors write. (THC’s intoxicating results are mediated by CB1, although the compound additionally binds to CB2; CBD doesn’t have a robust affinity for both.) In consequence, CBD has attracted growing consideration for its therapeutic potential.
Focusing on Cannabinoid Receptor 2 to Deal with Dementia
A second current overview, printed within the Journal of Neuroscience Analysis4 in early September, takes a barely completely different tack. As a substitute of specializing in plant cannabinoids, it attracts upon most of the similar elements linking the ECS with Alzheimer’s Illness to make a case for selectively focusing on CB2 (which doesn’t mediate psychotropic results) when creating novel medication to deal with Alzheimer’s and associated circumstances.
“Within the remedy of neurodegenerative ailments, CB2 agonists have proven promising outcomes,” the India-based authors write. (An “agonist” prompts a receptor and causes it to sign, whereas an antagonist blocks the receptor.) “The experimental proof means that they could be helpful within the administration of Alzheimer’s Illness by decreasing irritation, tau hyperphosphorylation, beta-amyloid aggregation, [and] oxidative stress, and enhancing cognitive perform.”
The paper cites quite a few examples of selective CB2 agonists developed and examined for treating ache, arthritis, irritation, and different circumstances by corporations together with GlaxoSmithKline, Glenmark Prescription drugs, Corbus Prescription drugs, and Eli Lilly. Up to now, nonetheless, medical scientists haven’t been in a position to translate early-phase scientific trials involving CB2 agonists into viable, clinically efficient prescribed drugs.
Alzheimer’s & Intestine Microbiota
In recent times the intestine microbiome has emerged as a captivating participant in human well being and illness. Disturbances to this technique have been related to a broad vary of opposed outcomes together with weight problems, most cancers, and (you guessed it) neurodegenerative problems reminiscent of Alzheimer’s and Parkinson’s.
Much less typically addressed in common accounts of the intestine microbiome are its interactions with the endocannabinoid system. As Undertaking CBD defined in a 2020 article, the ECS serves as a form of bridge between resident micro organism and the physique itself, together with the mind, by relaying alerts backwards and forwards inside this symbiotic, mutually helpful relationship.
In a current overview within the journal Life5 , a workforce of Italian researchers makes use of this similar metaphor to conceptualize how the ECS could also be key to mediating the connection between intestine flora dysbiosis and Alzheimer’s physiopathology. The 2 interacting techniques could function “widespread denominators” within the illness, the researchers recommend. “The overlapping roles of the encodcannabinoid system and the microbiome…recommend {that a} novel method reminiscent of modulating the microbiota by way of [the ECS] could present new therapeutic views for treating AD,” they conclude.
Nate Seltenrich, an unbiased science journalist primarily based within the San Francisco Bay Space, covers a variety of topics together with environmental well being, neuroscience, and pharmacology.
Copyright, Undertaking CBD. Might not be reprinted with out permission.
Footnotes
